BG60753B2 - Indометнасin с депо излъчване - Google Patents

Indометнасin с депо излъчване Download PDF

Info

Publication number
BG60753B2
BG60753B2 BG96105A BG9610592A BG60753B2 BG 60753 B2 BG60753 B2 BG 60753B2 BG 96105 A BG96105 A BG 96105A BG 9610592 A BG9610592 A BG 9610592A BG 60753 B2 BG60753 B2 BG 60753B2
Authority
BG
Bulgaria
Prior art keywords
indomethacin
pills
weight
coated
capsule
Prior art date
Application number
BG96105A
Other languages
Bulgarian (bg)
English (en)
Inventor
Robert Dempski
Gunvant Mehta
Joseph Saboe
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of BG60753B2 publication Critical patent/BG60753B2/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BG96105A 1978-12-11 1992-03-19 Indометнасin с депо излъчване BG60753B2 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/968,608 US4173626A (en) 1978-12-11 1978-12-11 Sustained release indomethacin

Publications (1)

Publication Number Publication Date
BG60753B2 true BG60753B2 (bg) 1996-02-29

Family

ID=25514496

Family Applications (1)

Application Number Title Priority Date Filing Date
BG96105A BG60753B2 (bg) 1978-12-11 1992-03-19 Indометнасin с депо излъчване

Country Status (3)

Country Link
US (1) US4173626A (fr)
BG (1) BG60753B2 (fr)
CA (1) CA1149742A (fr)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3278491D1 (en) * 1981-07-15 1988-06-23 Key Pharma Sustained release theophyline
US4587118A (en) * 1981-07-15 1986-05-06 Key Pharmaceuticals, Inc. Dry sustained release theophylline oral formulation
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
US4508702A (en) * 1982-06-14 1985-04-02 Key Pharmaceuticals, Inc. Sustained release aspirin
EP0111560A4 (fr) * 1982-06-14 1987-02-03 Key Pharma Aspirine a liberation entretenue.
US4634587A (en) * 1982-07-09 1987-01-06 Key Pharmaceuticals, Inc. Sustained release quinidine dosage form
EP0113373B1 (fr) * 1982-07-09 1991-08-28 Key Pharmaceuticals, Inc. Forme de dosage de quinidine a liberation entretenue
DK151608C (da) * 1982-08-13 1988-06-20 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse
DK152744C (da) * 1982-08-13 1988-10-31 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
JPS604120A (ja) * 1983-06-22 1985-01-10 Shionogi & Co Ltd 作用持続型ピナシジル製剤
US4505890A (en) * 1983-06-30 1985-03-19 E. R. Squibb & Sons, Inc. Controlled release formulation and method
US4652442A (en) * 1983-07-05 1987-03-24 Arcana Chem. Pharm. Fabrik Gesellschaft M.B.H. Process of producing a sustained release preparation containing indomethacin or niomethacin
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
IT1206166B (it) * 1984-07-26 1989-04-14 Sigma Tau Ind Farmaceuti Dispositivo per rilasciare una sostanza in un fluido di dissoluzione con cinetica di ordine zero e procedimento per la sua preparazione
KR850700212A (ko) * 1984-03-21 1985-12-26 죠지 드모트 서방성 약제학적 캼셀제
US4610870A (en) * 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
US5229132A (en) * 1985-02-22 1993-07-20 Grimberg Georges Serge Non-absorbable gastrointestinal medicament provided for treating the two levels of the digestive tract at the same time
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4666705A (en) * 1985-06-03 1987-05-19 E. R. Squibb & Sons, Inc. Controlled release formulation
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
EP0302065B1 (fr) * 1986-03-21 1994-08-10 Eurasiam Laboratories, Inc. Compositions pharmaceutiques
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4708834A (en) * 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
US4795642A (en) * 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
US4832957A (en) * 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4752470A (en) * 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
DK173505B1 (da) * 1987-02-20 2001-01-15 Pharmatec Internat S R L Fremgangsmåde til fremstilling af en diltiazempellet med langsom afgivelse og anvendelse af således fremstillede pelleter t
US4938968A (en) * 1988-07-26 1990-07-03 Norjec Development Associates, Inc. Controlled release indomethacin
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
SE8902699D0 (sv) * 1989-08-09 1989-08-09 Lejus Medical Ab Diltiazem containing pharmaceutical compositios
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
ATE114472T1 (de) * 1989-09-21 1994-12-15 American Cyanamid Co System des typs ''einmal täglich'' zur gepulsten minocyclinabgabe.
EP0418597A3 (en) * 1989-09-21 1991-11-27 American Cyanamid Company Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
TW209174B (fr) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
DE4140191C2 (de) * 1991-12-05 1998-02-19 Alfatec Pharma Gmbh Retardform für ein Indometacin oder Acemetacin enthaltendes Arzneimittel und seine Herstellung
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline
JPH09500645A (ja) * 1993-07-22 1997-01-21 ワーナー−ランバート・コンパニー 制御放出タクリン薬物送達システムおよびその製造方法
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
EP1133230A4 (fr) 1998-11-23 2004-05-26 Bonnie M Davis Formulations de dosage d'inhibiteurs de l'acetylcholinesterase
AU2697100A (en) * 1999-02-23 2000-09-14 Yuhan Corporation Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
JP4078074B2 (ja) 1999-12-10 2008-04-23 ファイザー・プロダクツ・インク ピロロ［２，３−ｄ］ピリミジン化合物
EA006079B1 (ru) * 2000-03-31 2005-08-25 Пфайзер Продактс Инк. Новые пиперазиновые производные
EP1318792B1 (fr) * 2000-09-22 2005-01-05 Galephar M/F Composition a liberation prolongee contenant de la clarithromycine
CZ20031013A3 (en) * 2000-10-19 2004-03-17 Pfizer Products Inc. Bridged piperazine derivatives
EE200400023A (et) * 2001-06-20 2004-06-15 Pfizer Products Inc. Uued sulfoonhappe derivaadid
ATE376826T1 (de) * 2001-09-28 2007-11-15 Mcneil Ppc Inc Darreichungsformen zur modifizierten freisetzung
US20040146559A1 (en) * 2002-09-28 2004-07-29 Sowden Harry S. Dosage forms having an inner core and outer shell with different shapes
US20040253312A1 (en) * 2001-09-28 2004-12-16 Sowden Harry S. Immediate release dosage form comprising shell having openings therein
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US20030228368A1 (en) * 2001-09-28 2003-12-11 David Wynn Edible solid composition and dosage form
DK1438298T3 (da) * 2001-10-22 2010-04-12 Pfizer Prod Inc Piperazin-derivater med CCR1 receptor-antagonist-aktivitet
MXPA04011231A (es) * 2002-05-14 2005-01-25 Pfizer Prod Inc Metodos para fabricar derivados de dihidro-furan-2-ona.
EP1503999A1 (fr) * 2002-05-14 2005-02-09 Pfizer Products Inc. Derives d'acide dihydroxyhexanoique, leurs intermediaires et procedes de preparation correspondants
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
US20040063717A1 (en) 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
PA8575901A1 (es) * 2002-07-18 2004-07-20 Pfizer Prod Inc Derivados de piperidina novedosos
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
OA12894A (en) * 2002-08-12 2006-10-13 Pfizer Prod Inc Crystal forms of quinoxaline-2-carboxylic acid [4-carbamoy 1-1-(3-fluorobenzyl)-2,7-dihydroxy-7-met hyl-octyl]-amide.
PL375979A1 (en) 2002-09-18 2005-12-12 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
US7807197B2 (en) * 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
PL377791A1 (pl) * 2002-11-21 2006-02-20 Pfizer Products Inc. Pochodne 3-aminopiperydyny i sposoby ich wytwarzania
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
KR20050086784A (ko) * 2002-11-26 2005-08-30 화이자 프로덕츠 인크. 이식 거부반응의 치료 방법
MXPA05006229A (es) * 2002-12-13 2005-08-19 Pfizer Prod Inc Derivados de piperazina que contienen fosforo como antagonistas de ccr1.
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
WO2004072072A1 (fr) * 2003-02-14 2004-08-26 Pfizer Products Inc. Triazolo-pyridines utilisees comme composes anti-inflammatoires
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
BRPI0408251A (pt) 2003-03-11 2006-03-01 Pfizer Prod Inc compostos de pirazina como inibidores do fator de crescimento transformante (tgf)
US20050119275A1 (en) * 2003-06-24 2005-06-02 Pfizer Inc. Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US20050074514A1 (en) * 2003-10-02 2005-04-07 Anderson Oliver B. Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms
EP1689407A1 (fr) * 2003-11-25 2006-08-16 Pfizer Products Inc. Methode de traitement de l'atherosclerose
US8067029B2 (en) * 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
EP1737449A1 (fr) * 2004-03-01 2007-01-03 LEK Pharmaceuticals D.D. Composition pharmaceutique
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8383159B2 (en) * 2004-10-27 2013-02-26 Mcneil-Ppc, Inc. Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088593A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
WO2007121537A1 (fr) 2006-04-26 2007-11-01 Alphapharm Pty Ltd Formulations à libération contrôlée qui comprennent une ou plusieurs unités discrètes non enrobées et une matrice à libération retardée
JP5389656B2 (ja) 2006-10-20 2014-01-15 マクニール−ピーピーシー・インコーポレーテツド アセトアミノフェン／イブプロフェンの組み合わせおよびこれらの使用方法
US20080317677A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
US20080317678A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
CA2704209C (fr) * 2007-10-31 2017-02-28 Mcneil-Ppc, Inc. Forme de dosage a desintegration orale
BRPI0821735A2 (pt) * 2007-12-21 2015-06-16 Mcneil Ppc Inc Fabricação de tablete
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
WO2009158368A1 (fr) * 2008-06-26 2009-12-30 Mcneil-Ppc, Inc. Particules enrobées contenant des agents pharmaceutiquement actifs
US10165772B2 (en) * 2008-08-21 2019-01-01 Édouard Kouassi Methods and compounds for increasing red blood cell survival
TW201038578A (en) 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ， インコーポレイテッド Ｃｎｓ障害の治療のためのラノラジン
US8858210B2 (en) 2009-09-24 2014-10-14 Mcneil-Ppc, Inc. Manufacture of variable density dosage forms utilizing radiofrequency energy
US9610224B2 (en) 2009-09-24 2017-04-04 Johnson & Johnson Consumer Inc. Manufacture of tablet in a die utilizing powder blend containing water-containing material
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
JP6117708B2 (ja) 2011-03-18 2017-04-19 ジェンザイム・コーポレーション グルコシルセラミド合成酵素阻害剤
JP2014513727A (ja) 2011-05-16 2014-06-05 ジェンザイム・コーポレーション Ｃｘｃｒ４拮抗薬の使用
CA2844577A1 (fr) 2011-09-13 2013-03-21 Ottawa Hospital Research Institute Inhibiteurs de micro-arn microrna inhibitors
CN102600475B (zh) * 2012-03-27 2013-05-22 珠海润都制药股份有限公司 一种药用微丸丸芯及制备方法
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
RU2019104092A (ru) 2013-03-13 2019-03-20 Бостон Байомедикал, Инк. Производные 3-(арил или гетероарил)метилениндолин-2-она в качестве ингибиторов киназного пути раковых стволовых клеток для лечения рака
US20150118229A1 (en) 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
KR20160107254A (ko) 2014-01-10 2016-09-13 존슨 앤드 존슨 컨수머 인코포레이티드 고주파 및 손실 코팅된 입자를 사용하여 정제를 제조하는 방법
RU2710928C2 (ru) 2014-07-31 2020-01-14 Инсерм (Институт Насьональ Де Ла Сант Эт Де Ла Решерш Медикаль) Антагонисты рецептора flt3
CA2936748C (fr) 2014-10-31 2017-08-08 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
MA41202A (fr) 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
EP3265462A1 (fr) 2015-03-03 2018-01-10 INSERM - Institut National de la Santé et de la Recherche Médicale Antagonistes de fgfr3
TW201642855A (zh) 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
WO2018007648A1 (fr) 2016-07-08 2018-01-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Composés de 4-anilino-quinoline utilises en tant qu'agents anticancéreux
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
JP7268053B2 (ja) 2018-01-05 2023-05-02 アンスティトゥート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシャルシュ・メディカル・（インセルム） 置換ハロキノリン誘導体、その調製方法及び適用
EP3860988A1 (fr) 2018-10-03 2021-08-11 Tesaro, Inc. Formes cristallines d'une base libre de niraparib
CN113166071A (zh) 2018-10-03 2021-07-23 特沙诺有限公司 尼拉帕利盐
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN113710249A (zh) 2019-02-04 2021-11-26 建新公司 用于治疗溶酶体贮积症相关的症状和病症的方法
WO2020163337A1 (fr) 2019-02-04 2020-08-13 Genzyme Corporation Traitement de ciliopathies à l'aide d'inhibiteurs de la glucosylcéramide synthase (gcs)
WO2021156769A1 (fr) 2020-02-03 2021-08-12 Genzyme Corporation Méthodes de traitement de symptômes neurologiques associés à des maladies lysosomales
BR112023000798A2 (pt) 2020-07-24 2023-02-07 Genzyme Corp Composições farmacêuticas compreendendo venglustat
CN116322663A (zh) 2020-09-30 2023-06-23 比奥维拉迪维治疗股份有限公司 Ampk激活剂及其使用方法
TW202241888A (zh) 2020-12-23 2022-11-01 美商健臻公司 氘化群落刺激因子-1受體(csf-1r)抑制劑
WO2023196640A1 (fr) 2022-04-08 2023-10-12 Bioverativ Therapeutics Inc. Dérivés d'oxindole en tant qu'activateurs d'ampk destinés à être utilisés dans le traitement de troubles du sang rare

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR732895A (fr) 1932-10-18 1932-09-25 Consortium Elektrochem Ind Objets filés en alcool polyvinylique
CH283585A (de) * 1950-03-15 1952-06-15 Hoffmann La Roche Zur Herstellung von Tablettenüberzügen geeignetes Gemisch.
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
US2928770A (en) * 1958-11-28 1960-03-15 Frank M Bardani Sustained action pill
US3081233A (en) * 1960-08-08 1963-03-12 Upjohn Co Enteric-coated pilules
NL270408A (fr) * 1960-10-20
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3325365A (en) * 1963-04-02 1967-06-13 Ciba Geigy Corp Enteric composition for tablet compression coating
US3383236A (en) 1964-04-17 1968-05-14 Merck & Co Inc Continuous pharmaceutical film coating process
US3400185A (en) * 1965-04-08 1968-09-03 Bristol Myers Co Agglomeration of smaller pharmaceutical particles into larger microspherules and enteic-coating thereof
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
NL7112083A (fr) 1970-09-16 1972-03-20
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform

Also Published As

Publication number Publication date
US4173626A (en) 1979-11-06
CA1149742A (fr) 1983-07-12

Similar Documents

Publication Publication Date Title
BG60753B2 (bg) Indометнасin с депо излъчване
JP3631762B2 (ja) トラマドール複式ユニット製剤
US4689233A (en) Coronary therapeutic agent in the form of soft gelatin capsules
FI78835C (fi) Foerfarande foer framstaellning av en ny dipyridamol-retardform.
US4415547A (en) Sustained-release pharmaceutical tablet and process for preparation thereof
US5122384A (en) Oral once-per-day organic nitrate formulation which does not induce tolerance
NZ201008A (en) Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient
JP2013063982A (ja) バルデナフィル塩酸塩三水和物を含む薬剤
JPH0643312B2 (ja) 薬学的調合剤
NO175351B (no) Fremgangsmåte ved fremstilling av legemiddelformer for oral bruk inneholdende 9-deokso-11-deoksy-9,11-(imino(2-(2-metoksyetoksy) etyliden)-oksy)-(9S)-erytromycin
CZ20011539A3 (cs) Mnohočásticový modifikovaně uvolňující prostředek a jeho pouľití a pevná orální dávkovací forma
HU196708B (en) Process for producing pharmaceutical composition comprising omeprazol and suitable for treating deseases of the digestive system
GB2128088A (en) Oral mopidamol preparations
CN108066319B (zh) 一种枸橼酸托法替布肠溶缓释微丸及其制备方法
RU2008136766A (ru) Таблетки метопролола сукцината пролонгированного действия и способы их приготовления
US7135465B2 (en) Sustained release beadlets containing stavudine
GB2204241A (en) Fat coated pharmaceutical compositions
WO2005084649A1 (fr) Préparation de capsule stable
EP1131072A2 (fr) Specialite pharmaceutique combinee
WO1994007494A1 (fr) Nouvelles compositions administrees par voie orale contenant 1,2,5,6-tetrahydro-1-methyl-3-pyridinecarboxyaldehyde-o-methyl-oxime
KR20090029830A (ko) 소장 내에서 활성성분의 방출이 제어되는 경구투여용 약제학적 조제물 및 그의 제조방법
JP2019512537A (ja) ダパグリフロジンの医薬組成物
AU1456999A (en) Novel oral dosage form for carvedilol
US3485914A (en) Process for the production of a pharmaceutical antibiotic preparation having delayed therapeutic action and the composition prepared according to such process
RU2188018C2 (ru) Композиционный состав антибактериального лекарственного средства